Yuewei Medical Secures Tens of Millions in A++ Round to Advance Innovative Cardiovascular Devices

Investment Circle (ID: pedaily2012) News on April 3rd, according to Arterial Network reports, Yellwin, a company focused on the research and development of innovative medical devices for cardiac surgery, announcedCompleted a multi-million yuan A++ round of financing exclusively invested by the Beijing Pharmaceutical and Health Industry Investment Fund.

This round of financing will mainly be used in two directions: one is to deepen the development of innovative devices for the entire process of coronary heart disease diagnosis and treatment, as well as new products such as pulsatile left ventricular assist systems; the other is to accelerate the market promotion of products that have already been approved for marketing, such as cardiac stabilizers. Through the empowerment of this round of financing, Yellwin will comprehensively strengthen its R&D innovation and market penetration capabilities in the cardiovascular field, and continue to consolidate its leading position in technology.

Yellwin was founded in September 2021 by the cardiac surgery team from Anzhen Hospital and senior executives from the medical device industry. Headquartered in Beijing, the company has assembled a multidisciplinary team with expertise in clinical medicine, medical device hardware, and AI algorithms. Drawing on the founding team's extensive clinical experience in cardiac surgery, Yellwin identifies unmet clinical needs and develops innovative medical devices tailored to current industry advancements. These include China’s first next-generation heart stabilizer, a vascular anastomosis quality control system, and a coronary artery disease scoring system, all of which fill critical market gaps. The company holds over 50 patents globally and is recognized as a national high-tech enterprise and a specialized, refined, and innovative enterprise.

Dr. Yu Wenyuan, Co-founder and CEO of Yellwin, stated:Thank you to the Beijing Medical and Health Industry Investment Fund for their trust and support in the Yellwin team. Starting a business is challenging, and on one hand, we will continue to work hard on commercialization, striving to achieve positive operating cash flow as soon as possible. On the other hand, we will not forget our original aspirations and always remember that we are a company serving doctors and patients—product innovation will forever be our core competitiveness. As a company primarily composed of a doctor team, Yellwin is familiar with the needs of clinical doctors in terms of scientific research transformation and has some understanding of the medical device development process. We also welcome doctors who have needs for scientific research transformation to contact us.

Yellwin Chief Scientist Professor Yu Yang stated:"Originating from clinical practice, surpassing clinical practice, and returning to clinical practice" is the core concept of Yellwin's product development. To implement this concept, we have improved existing devices by addressing their shortcomings, leading to the creation of multiple products such as the Yellwin heart stabilizer and proximal anastomosis system. Additionally, we have accelerated progress in the field of domestic alternatives, developing China’s first domestically produced vascular anastomosis quality control system and femoral artery-vein cannulae. Furthermore, to align with the trends towards minimally invasive and critical care, we have developed the world’s first high-flow, pulsatile percutaneous left ventricular assist system that operates without DSA assistance. In the future, we will continue to develop several groundbreaking innovative devices, such as a minimally invasive small vessel anastomosis system, ensuring that Yellwin becomes a company that is both firmly established and capable of long-term growth.

Beijing Medical and Health Industry Investment Fund stated:The company focuses on the research and development of innovative medical devices in the field of cardiac surgery. Based on unmet clinical needs in China and the team's extensive first-line clinical experience, it fully leverages the interdisciplinary advantages of combining medical and engineering expertise. The company develops life-support equipment and solutions covering the entire diagnosis and treatment process for major diseases such as coronary heart disease and heart failure. The product pipeline balances R&D innovation with commercial viability, progressively addressing and filling various niche market gaps in China.